The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Company to launch product after the expiry of semaglutide patent in India
Jagsonpal Pharmaceuticals has reported total income of Rs. 75.92 crore during the period ended December 31, 2025
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Medico Remedies has secured the order to supply Azithromycin 500gm (tablets) to Uttar Pradesh Medical Supplies Corporation Limited
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Subscribe To Our Newsletter & Stay Updated
